Pfizer (PFE) Stock Price Forecast: 2026, 2027, 2028–2030 and Beyond

2026.04.28 2026.04.28 Pfizer (PFE) Stock Price Forecast: 2026, 2027, 2028–2030 and Beyond

Jana Kanehttps://www.litefinance.org/blog/authors/jana-kane/

Pfizer (#PFE) stocks have garnered considerable attention from investors thanks to their promising upside potential and highly active market conditions. Amid global economic volatility and new healthcare challenges, #PFE offers a compelling option for both short- and long-term investments.

Forecasts for the coming years show a wide range of potential prices, reflecting possible fluctuations and yield increases. Analyzing current trends and seasonal movements presents a unique opportunity to identify optimal market entry points and assess investment risk. 

This article provides an in-depth analysis of Pfizer stocks, helping you grasp the intricacies of the market and empowering you to make more informed trading decisions.

Major Takeaways

• The PFE stock price is trading at $25.31 as of 16.05.2026.
• The PFE price reached its all-time high of $61.25 on 16.12.2021. The stock's all-time low of $0.43 was recorded on 04.10.1974.
• In 2024, the company implemented strategic initiatives to optimize its product lineup and expand its global footprint.
• The PFE stock is traded on the New York Stock Exchange (NYSE) under the ticker symbol #PFE, making it accessible to a wide range of investors.
• The company maintains stable operating profit by actively investing in research and innovation.
• Free cash flow makes it possible to finance new projects and maintain a proper dividend policy.
• Forecasts for 2026 are mixed. Pfizer shares may rise to the $34.00–$40.00 range, though some analysts expect the PFE price to fall to $22.00–$26.00 during the year.
• Forecasts for 2027 remain mixed. Optimistic scenarios point to growth in the $39.00–$50.00 range, while more pessimistic projections suggest a decline to $14.00–$21.00.
• For the 2028–2030 period, expectations also vary. Some analysts anticipate stabilization followed by a rise to $30.00–$46.00, whereas others foresee a gradual decline toward $10.00.
• Long-term outlooks diverge significantly. Some projections suggest that Pfizer shares may recover, while others expect the downward trajectory to persist.

Pfizer (PFE) Real-Time Market Status

The current Pfizer (#PFE) stock price is $25.31 as of 16.05.2026.

Investors should monitor key metrics that help assess the financial strength of a company, upside potential, and stock liquidity. For example, market capitalization indicates the overall value of the company, while trading volume reflects market activity. The P/E ratio assesses stock profitability, and the price change over the last 12 months helps to assess the stock's performance. Additionally, dividend yield and maximum supply help gauge shares' profitability and availability.

Pfizer (PFE) Stock Price Forecast for 2026 Based on Technical Analysis

PFE shares have been under pressure for an extended period. However, the downtrend has begun to reverse in recent months, with the price gradually shifting higher on the chart. The price has settled above $25.00 and is attempting to climb toward $28.00–$29.00. The current structure most likely signals a transition from a downtrend to a sideways movement with a moderate upward bias.

The SMA50 is turning higher and gradually converging with the SMA200, signaling a weakening downtrend and potential stabilization. The MACD is hovering near the zero line, indicating limited momentum, while the RSI remains in neutral territory, reinforcing the view of an accumulation phase.

The base-case scenario points to sideways movement, with intermittent upward moves and periodic pullbacks toward support.

Below are the #PFE share price estimates for the next 12 months.

Long-Term Trading Plan for #PFE for 2026

According to technical analysis, the main strategy for 2026 is to find entry points for buying on pullbacks within the support zone of $25.00–$26.00. Entries should be considered when indicators show signs of stabilization and a reversal. The nearest targets are $28.00–$30.00, with partial profit-taking as the price rises. If the price firmly consolidates above these levels, part of the position can be held to capture a continuation of the uptrend.

An alternative scenario involves a return below $25.00, which would indicate a weakening of the current recovery and serve as a signal to adjust positions to reduce risk.

Analysts' PFE Share Price Projections for 2026

Analysts differ in their assessments of Pfizer's stock performance in 2026, as it is difficult to predict the company's future revenues from novel drug products. Reports on clinical trials of new cancer treatments, as well as regulatory changes, could trigger sharp fluctuations in PFE's stock price.

CoinCodex

Price range: $22.92–$29.59.

According to CoinCodex, the price will reach a swing high of $29.59 in May. A downward trend is then expected, with the price falling to $22.92 in September. By the end of the year, a recovery to previous levels is possible. The average price may reach $28.12 in December.

StockScan

Price range: $21.46–$40.37.

StockScan analysts predict that PFE's price will experience a sustained upward trend throughout 2026. Following the May low of $21.46, the price is expected to begin a steady rise. In August, the price will likely rise to $28.46, and in November, it may reach a high of $40.37.

LongForecast

Price range: $23.49–$39.33.

LongForecast expects bullish sentiment to prevail in 2026, leading to an increase in PFE shares' price. A brief decline to $23.49 is forecast in May, after which the price is likely to begin a steady recovery, reaching $34.12 by September. By the end of the year, the upward trend may strengthen, with the price potentially reaching a high of $39.33.

Analysts' PFE Share Price Projections for 2027

According to most forecasts, Pfizer's stock is expected to trend downward in 2027. The expiration of key patents and the need to increase spending on new research and development could put pressure on the stock price.

Note: The price ranges reflect the asset's expected volatility throughout the year. Lows and highs may not be shown in the summary tables.

CoinCodex

Price range: $14.37–$27.87.

According to CoinCodex, PFE is expected to decline in value in 2027. The price may reach a high of $27.87 in the first quarter. After that, it may fall to $19.70 by June. By the end of the year, the downward trend may intensify, with the price dropping to $14.37.

StockScan

Price range: $29.60–$50.54.

StockScan predicts that PFE's share price will see active growth in the first half of 2027, followed by a correction. The price is expected to reach a high of $50.54 in the second quarter, after which the trend will turn downward. According to the forecast, the maximum price at the end of the year will not exceed $43.81.

LongForecast

Price range: $35.35–$46.82.

LongForecast anticipates that PFE will trade within a broad sideways range. The price is expected to rise to $42.04 by the second quarter and reach a yearly high of $46.82 in the third quarter. A correction to around $36.04 is possible by the end of the year.

Analysts' PFE Share Price Projections for 2028

In 2028, Pfizer's stock is expected to see mixed performance due to the anticipated completion of major share buyback programs. Investors may also focus on revenue figures from previously acquired biotechnology companies and the integration of new products into the commercial pipeline.

CoinCodex

Price range: $13.53–$16.80.

CoinCodex predicts a prolonged sideways trend. At the start of the year, prices may settle near $14.12, likely followed by a brief spike to a high of $16.80 in July. The price will drop to $13.53 by November.

StockScan

Price range: $25.96–$44.65.

According to StockScan, PFE is expected to trend downward. In the second quarter, the price may surge to a high of $44.65, but a gradual decline is likely to follow. Analysts predict that by the end of the fourth quarter, the price will fall to a yearly low of $25.96.

LongForecast

Price range: $33.88–$49.79.

LongForecast suggests that Pfizer shares will increase in 2028. The yearly low will be reached in the first quarter at $33.88. By the end of the first half of the year, the average price may soar to $42.98, and by the end of the year, the price is forecast to reach a high of $49.79.

Analysts' PFE Share Price Projections for 2029

Analysts predict a predominantly bearish trend for Pfizer shares in 2029 due to pressure from government programs to lower drug prices. Potential changes in patent law and macroeconomic turmoil are prompting analysts to factor in the possibility that the stock could hit multi-year lows.

CoinCodex

Price range: $11.81–$14.83.

According to CoinCodex, the PFE price will see a downward trend in 2029, with brief periods of stabilization expected. The average price in the first quarter is expected to trade near $14.26, then decline to a swing low of $11.18. By the end of the year, a recovery to $14.83 is possible.

StockScan

Price range: $12.93–$28.06.

StockScan forecasts a decline in Pfizer's stock price throughout 2029. The price is expected to peak in January at $28.06, after which it will begin to decrease. By the end of July, the average price could drop to $20.69, and by the end of December, it could fall to $16.28.

LongForecast

Price range: $36.44–$52.28.

According to LongForecast, PFE shares are expected to trade sideways in 2029, reaching a high of $52.28 in the first quarter. In the second quarter, a gradual pullback to $47.38 is expected. By the end of the year, the downward trend is projected to intensify, with the price reaching $41.13.

Analysts' PFE Share Price Projections for 2030

Analysts' forecasts for 2030 are largely pessimistic, anticipating a prolonged downtrend for Pfizer. The company’s stock price is likely to come under pressure due to the eventual expiration of patent protection for its key products and the high cost of servicing its accumulated debt.

CoinCodex

Price range: $12.49–$16.12.

CoinCodex predicts a sideways trend, with a gradual decline in PFE's price. In the second quarter, the price may approach $16.12, but momentum will quickly fade, bringing prices back to the $13.52 support level in September. By the end of the year, bears are likely to ramp up the pressure, dragging the price to a low of $12.49.

StockScan

Price range: $2.43–$17.83.

StockScan forecasts a precipitous decline in the stock price. Pfizer is expected to reach a swing high of $17.83 in February, after which the uptrend will finally reverse. The average price in the second quarter is expected to trade near $9.79. By December, analysts expect sellers to gain the upper hand, causing the stock to plummet to a low of $2.43.

Analysts' PFE Share Price Projections until 2050

It is extremely difficult to forecast Pfizer's (PFE) performance over a 25-year horizon, which is why major analytical platforms rarely publish such long-term scenarios. The pharmaceutical industry is inherently volatile and heavily influenced by the pace of technological progress, changes in healthcare systems, and the success of bringing new therapies to market.

Nevertheless, long-term benchmarks for Pfizer through 2050 can help assess its potential growth trajectory and balance risks against expected returns.

CoinPriceForecast maintains a positive outlook, projecting the stock to reach $45.90 by mid-2035 and stabilize around $50.67 by 2037.

StockScan presents a bearish scenario, expecting a decline to $11.62 by 2035 and a further drop to $9.02 by 2040.

Market Sentiment for Pfizer (PFE) on Social Media

Media sentiment plays a significant role in shaping short-term expectations and influencing market behavior. During periods of uncertainty, media coverage can amplify emotions, leading to heightened price volatility. Trader sentiment becomes an additional driver, particularly when prices approach key technical levels.

For example, a user on the social media platform X (formerly Twitter) with the nickname @CapitalWisdomAI points out a sell signal while noting insider buying and anticipating a price increase.

User @NomadiCapital leans toward a positive scenario. The post suggests that the market is likely to bottom out and gradually recover, with no significant decline expected from current levels.

Overall, sentiment remains subdued: market participants anticipate growth but do not expect strong momentum, so they remain cautious in their assessments.

Pfizer (PFE) Price History

Pfizer reached the highest price of $61.25 on 16.12.2021. The lowest price of Pfizer was recorded on 04.10.1974 when the stock declined to $0.43.

The chart below shows the #PFE price performance over the last ten years. It is crucial to evaluate historical data to make our forecasts as accurate as possible.

Pfizer's share price has hit several key milestones since the early 2000s:

• In 2000, the #PFE price hit a record high of about $50, bolstered by the successful launch of blockbuster drugs such as Viagra, Lipitor, and Zoloft.
• From 2004 to 2009, the #PFE price plunged to $12–$15 due to the company losing several patents and facing heightened competition. Moreover, the global financial crisis of 2008 contributed to these challenges.
• From 2013 to 2019, Pfizer's share price stabilized in the $35–$45 range thanks to advances in oncology, vaccines, biopharmaceuticals, and a solid dividend policy.
• In 2021, the asset set an all-time high of $61 as sales of Comirnaty, a vaccine developed with BioNTech, generated record revenue for the company.
• In 2023–2025, demand for the vaccine dropped sharply, consequently reducing revenue, and the #PFE price plummeted to $25–$30.
• In 2025, Pfizer shares remained confined to a narrow range of $20.91–$27.69 as sales of several drugs slowed.
• In the first half of 2026, the PFE price consolidated within the $25.00–$28.00 range ahead of the company's earnings reports.

The Pfizer stock has historically demonstrated the capacity to recover from severe downturns, indicating future upside potential.

Pfizer (PFE) Fundamental Analysis

Fundamental analysis plays a key role in forecasting the price of any asset. It involves assessing financial data, the company's market position, and other indicators affecting the #PFE rate.

What Factors Affect the Pfizer (PFE) Stock?

• Financials. The company's revenues, net income, profitability, and cash flows.
• Development and market launch of new drugs. Successful clinical tests and regulatory approvals.
• Patent protection. Expiration of patents on key drugs, the emergence of generics.
• Mergers and acquisitions. Strategic deals that expand product range and distribution markets.
• Regulatory environment. Changes in healthcare legislation and policy.
• Global economic conditions. Economic crises, currency fluctuations, and geopolitical instability.
• Competition. Actions of major competitors and innovation in the industry.
• Reputational risks. Lawsuits, fines, and public opinion.
• Dividend policy. Changes in the amount and regularity of payments to shareholders.
• Investor sentiment. General trends in the stock market and investors' attitudes to the pharmaceutical sector.

Given these factors, investors can objectively assess the prospects of the Pfizer stock and make more informed decisions.

More Facts About Pfizer (PFE)

Pfizer Inc. is a prominent American biopharmaceutical company founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York. The company develops, produces, and sells drugs and vaccines to treat various diseases. Pfizer is particularly well-known for its flagship products, such as Lipitor (atorvastatin) to lower cholesterol, Viagra (sildenafil) to address erectile dysfunction, and Prevenar, a pneumococcal vaccine.

In 2020, Pfizer, in collaboration with the German company BioNTech, developed Comirnaty, one of the first COVID-19 vaccines based on mRNA technology, which significantly boosted Pfizer's global profile. The company is actively investing in research and development to expand its range of innovative medicines and solidify its position in the global pharmaceutical market.

Advantages and Disadvantages of Investing in Pfizer (PFE)

Pfizer is one of the largest pharmaceutical companies, producing popular and effective medications. Moreover, it adheres to a solid dividend policy, making the #PFE stock a safe investment option. However, like any other asset, #PFE carries not only benefits but also risks.

Advantages

• Stable pharmaceutical business. Wide range of high-demand drugs and vaccines.
• Dividend payouts. The yield is above the market average (~5%).
• Innovation leadership. Significant investments in R&D and breakthrough drugs (oncology, vaccines).
• Defensive asset. Demand for drugs remains strong even during crises.
• Global expansion. Operations in key pharmaceutical markets.
• Government support. Cooperation with regulators and research funding.
• Access to new technologies. Regular acquisitions of biotech companies.

Disadvantages

• Declining post-COVID revenues. Falling demand for vaccines and drugs used for COVID-19 treatment.
• Dependence on regulators. FDA approvals and patent litigation can impact revenue.
• Risk of patent expiration. Loss of exclusive rights reduces revenues (Lipitor is an example).
• High competition. Competing with other pharma giants for market and innovation.
• Long development cycle. Clinical tests can take years, and failures lead to significant losses.
• Sensitivity to macroeconomics. Drug price regulation, inflation.
• Stock fluctuations. Despite the stability of this field, the PFE price is susceptible to market trends.

Pfizer (PFE) is a resilient pharmaceutical company known for its solid dividends and opportunities for growth through innovation. However, investors should keep in mind that the stock price might be influenced by factors such as declining post-COVID earnings, upcoming patent expirations, and intense competition. Although the asset is suitable for long-term investments, it is essential to assess the associated risks thoroughly.

How We Make Forecasts

Stock prices are forecast based on three time frames.

• Short-term forecasts (up to 6 months) rely on technical analysis (support/resistance levels, indicators, volumes) and news. Macroeconomic events, reports, and market reactions are taken into account.
• Medium-term forecasts (from 6 months to 3 years) include fundamental analysis (financial indicators, competitive advantages, sales trends). Macroeconomic trends, interest rates, geopolitics, and the company's product cycle are assessed.
• Long-term forecasts (3 years or more) are focused on strategic analysis. Industry potential, innovation, growth prospects, capital management, and global factors are explored. Besides, discounted cash flow (DCF) models and multiple valuations are also used.

However, each new forecast requires adjustment to align with the latest data and evolving market conditions.

Conclusion: Is Pfizer (PFE) a Good Investment?

Pfizer is a large company with an extensive product lineup, stable cash flows, and innovative technologies. However, the decision to invest depends on your financial goals and risk tolerance.

On the one hand, the company pays dividends and can increase its profits through new drugs and expansion into new markets. On the other hand, the pharmaceutical industry is highly regulated and competitive. Therefore, prior to making trading decisions, it is essential to review financial reports, company news, and expert forecasts. Those who prefer to avoid excessive risk may consider PFE as a suitable asset for a long-term portfolio.

Price chart of PFE in real time mode